An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non–muscle-invasive bladder cancer: Interim…

Overview of attention for article published in Urologic Oncology, July 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#13 of 2,928)
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 8 news outlets
twitter: 4 X users
patent: 11 patents

wikipedia: 1 Wikipedia page
guideline: 4 clinical guideline sources

Readers on

mendeley: 182 Mendeley

So far, Altmetric has seen 11 news stories from 8 outlets.

CG Oncology's Promising Bladder Cancer Treatment: Balancing Hope And Risk In Late-Stage Trials

Seeking Alpha, 03 May 2024

Follow Summary CG Oncology has entered the public market with late-stage clinical trials for its cancer therapy, cretostimogene…

This Startup Wants To Fight Bladder Cancer With A Genetically Engineered Virus

Forbes, 02 Aug 2023

CG Oncology, led by Forbes 30 Under 30 alum Arthur Kuan, wants to supplant the current treatment for a form of cancer that’s…

CG0070 Plus Pembrolizumab Produces Durable Responses in BCG-Unresponsive NMIBC

OncLive, 18 May 2023

Roger Li, MD, discusses how the synergistic mechanism of pembrolizumab plus CG0070 could address unmet needs in BCG-unresponsive…

AskByGeeks | ‘Wonderful’, ‘remarkable’ results of oncolytic virus combination in bladder cancer

AskByGeeks, 01 May 2023

CHICAGO – Combining oncolytic virotherapy with pembrolizumab (Keytruda) produced a complete response (CR) in 85% of patients…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 7 additional news stories.